Oveporexton
| Clinical data | |
|---|---|
| Trade names | Orzeyful |
| Other names | TAK-861; TAK861 |
| AHFS/Drugs.com | |
| License data |
|
| Routes of administration | Oral |
| Drug class | Orexin OX2 receptor agonist |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | >96% |
| Metabolism | CYP3A4 |
| Onset of action | 1–4 hours (Tmax) |
| Elimination half-life | 16–24 hours |
| Excretion | Feces: 80.5% Urine: 11.0% |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C23H25F5N2O4S |
| Molar mass | 520.52 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Oveporexton, sold under the brand name Orzeyful, is a medication used for the treatment of narcolepsy type 1. It is taken by mouth.
The most common side effects include insomnia, increased urinary frequency, urgency to urinate, and increased saliva production. Oveporexton is an orexin OX2 receptor agonist.
Oveporexton was approved for medical use in China in July 2026, and in the United States in August 2026. It is recommended for scheduling under the Controlled Substances Act and will be lawful to market in the US following the scheduling decision issued by the Drug Enforcement Administration.